Tempus AI announced the results of the ALERT (Addressing undertreatment and Health Equity in aortic stenosis and mitral regurgitation using an integrated EHR platform) trial, a cluster‑randomized study presented at the American College of Cardiology’s 75th Annual Scientific Session & Expo. The study evaluated an automated EHR‑based notification system designed to address undertreatment of significant valvular heart disease.
The trial reported a 40% relative increase in life‑saving valve procedures and a 27% relative increase in multidisciplinary heart‑team evaluations within 90 days of the alert. A win ratio of 1.27 (P = 0.007) underscored the effectiveness of the alerts. The study involved 765 clinicians, 2,016 echocardiograms, and was conducted across five U.S. health systems and 35 hospitals.
Valvular heart disease remains a leading cause of morbidity and mortality. Untreated symptomatic severe aortic stenosis carries a mortality rate approaching 50% within two years, while untreated severe mitral regurgitation has a median survival of only five years. The ALERT trial demonstrates that AI‑driven alerts can accelerate timely treatment and improve outcomes for these high‑risk patients.
The results reinforce Tempus’s strategy of leveraging its AI platform to improve clinical decision‑making and patient outcomes. The partnership with Medtronic and the positive data enhance the commercial potential of the ALERT system and support wider adoption across health systems.
"The ALERT trial shows that data‑driven clinical decision support positively impacts patients suffering from valvular heart disease," said Brandon Fornwalt, MD, PhD, Senior Vice President of Cardiology at Tempus. "By delivering timely, actionable insights directly to clinicians, this approach helps ensure more patients receive the evaluations and life‑saving interventions they urgently need. We are proud to collaborate on research that not only improves pathways to treatment but also supports more equitable care across diverse patient populations," added a Medtronic representative. "Being a part of this work further underscores our commitment at Tempus to building technology that helps every patient have the chance to receive the best possible care," added a Tempus spokesperson.
The trial also aimed to confront disparities in care for women, older adults, racial and ethnic minorities, and rural residents. The AI‑driven alerts act as a safety net to standardize care and reduce inequities, aligning with Tempus’s broader mission of health equity.
The ALERT trial provides evidence that AI‑driven EHR alerts can improve treatment of severe heart valve disease, supporting Tempus’s precision medicine platform and positioning the company for future growth.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.